DCM
DAFNA Capital Management Portfolio holdings
AUM
$440M
1-Year Est. Return
109.12%
This Fund
S&P 500
1 Year Est. Return
+109.12%
AUM
$440M
AUM Growth
+$9.07M
(+2.1%)
Holding
87
Top Buys
| 1 | +$10.8M | |
| 2 | +$5.13M | |
| 3 | +$4.36M | |
| 4 |
BCAX
Bicara Therapeutics
BCAX
|
+$2.76M |
| 5 |
Fulcrum Therapeutics
FULC
|
+$1.9M |
Top Sells
| 1 | +$9.76M | |
| 2 | +$7.38M | |
| 3 | +$3.99M | |
| 4 |
Revolution Medicines
RVMD
|
+$2.41M |
| 5 |
State Street SPDR S&P Biotech ETF
XBI
|
+$2.25M |
Sector Composition
| 1 | Healthcare | 87.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Foghorn Therapeutics
FHTX
$251M
| $535K | 0.12% |
111,859
-15,000
|
|
||
77
iBio
IBIO
$94.4M
| $368K | 0.08% |
+193,638
|
|
||
|
BCYC
78
Bicycle Therapeutics
BCYC
$327M
| $299K | 0.07% |
64,492
|
|
||
79
ADC Therapeutics
ADCT
$432M
| $270K | 0.06% |
72,081
-5,000
|
|
||
80
Karyopharm Therapeutics
KPTI
$206M
| $255K | 0.06% |
45,800
-5,200
|
|
||
|
AUTL
81
Autolus Therapeutics
AUTL
$498M
| $247K | 0.06% |
179,316
|
|
||
82
Neumora Therapeutics
NMRA
$343M
| $137K | 0.03% |
+70,000
|
|
||
83
Erasca
ERAS
$3.99B
| – | – |
-254,436
|
|
||
84
Perspective Therapeutics
CATX
$449M
| – | – |
-50,000
|
|
||
|
BWAY
85
Brainsway
BWAY
$637M
| – | – |
-25,930
|
|
||
|
ATXS
86
DELISTED
Astria Therapeutics
ATXS
| – | – |
-304,775
|
|